Earlie Smith experienced an aortic dissection. Months later, her brother, Larry Smith, also had one. The same doctor helped ...

Additionally, the AMDS device received a Humanitarian Device Exemption, enabling its use in a substantial portion of the DeBakey Type I dissections market. This exemption, coupled with the ...

Oppenheimer reiterated its Outperform rating on Artivion Inc. (NYSE: AORT) shares, maintaining a $32.00 price target. The stock has shown remarkable momentum, delivering an 82% return over the past ...

Oppenheimer reiterated its positive stance on Artivion Inc. (NYSE:AORT), maintaining an Outperform rating and a $32.00 price target. The endorsement comes on the heels of Artivion's presentation of ...

Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking ...

Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI ... days attributed to comorbidities and dissection-related complications.

The AMDS is an aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections ... days attributed to comorbidities and dissection-related complications.

PERSEVERE is a prospective, multicenter, nonrandomized clinical trial to determine if patients with acute DeBakey type I aortic dissection can be treated safely and effectively using the AMDS device.

Further studies are needed to determine whether prophylactic stent graft placement will improve outcomes in a selected subset of patients with uncomplicated descending aortic dissection.